Literature DB >> 29731229

Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.

S Hescot1, M Haissaguerre2, P Pautier3, E Kuhn4, M Schlumberger5, A Berdelou5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29731229     DOI： 10.1016/j.ejca.2018.04.001

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  9 in total

1.  The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System.

Authors:  Emanuel Raschi; Michele Fusaroli; Francesco Massari; Veronica Mollica; Andrea Repaci; Andrea Ardizzoni; Elisabetta Poluzzi; Uberto Pagotto; Guido Di Dalmazi
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

2.  Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.

Authors:  Virginie Grouthier; Bénédicte Lebrun-Vignes; Melissa Moey; Douglas B Johnson; Javid J Moslehi; Joe-Elie Salem; Anne Bachelot
Journal:  Oncologist       Date:  2020-05-17

Review 3.  Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults.

Authors:  C Betterle; F Presotto; J Furmaniak
Journal:  J Endocrinol Invest       Date:  2019-07-18       Impact factor: 5.467

4.  French Endocrine Society Guidance on endocrine side effects of immunotherapy.

Authors:  F Castinetti; F Albarel; F Archambeaud; J Bertherat; B Bouillet; P Buffier; C Briet; B Cariou; Ph Caron; O Chabre; Ph Chanson; C Cortet; C Do Cao; D Drui; M Haissaguerre; S Hescot; F Illouz; E Kuhn; N Lahlou; E Merlen; V Raverot; S Smati; B Verges; F Borson-Chazot
Journal:  Endocr Relat Cancer       Date:  2019-02       Impact factor: 5.678

5.  Editorial: From Chronic Inflammation to Cancer: How Far Can Immunotherapy Go?

Authors:  Xuefeng Li; Lesheng Teng; Zhaogang Yang
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.810

Review 6.  Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.

Authors:  Adrian Chye; India Allen; Megan Barnet; Deborah L Burnett
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

7.  Sick sinus syndrome associated with anti-programmed cell death-1.

Authors:  Chien-Yi Hsu; Yu-Wen Su; San-Chi Chen
Journal:  J Immunother Cancer       Date:  2018-07-16       Impact factor: 13.751

Review 8.  Biointerface engineering nanoplatforms for cancer-targeted drug delivery.

Authors:  Huaiyu Zhang; Shujun Dong; Zhongmin Li; Xiangru Feng; Weiguo Xu; Catrina Mae S Tulinao; Yang Jiang; Jianxun Ding
Journal:  Asian J Pharm Sci       Date:  2019-12-30       Impact factor: 6.598

Review 9.  Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer.

Authors:  Hannah Elizabeth Green; Jorge Nieva
Journal:  J Investig Med       Date:  2021-06-14       Impact factor: 2.895
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.